68 related articles for article (PubMed ID: 31160603)
21. Viewing the Eph receptors with a focus on breast cancer heterogeneity.
Nikas I; Ryu HS; Theocharis S
Cancer Lett; 2018 Oct; 434():160-171. PubMed ID: 30055288
[TBL] [Abstract][Full Text] [Related]
22. Cadherin-11 and Its Role in Tissue Fibrosis.
Chavula T; To S; Agarwal SK
Cells Tissues Organs; 2023; 212(4):293-303. PubMed ID: 35662129
[TBL] [Abstract][Full Text] [Related]
23. EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.
Yoon S; Choi JH; Kim SJ; Lee EJ; Shah M; Choi S; Woo HG
Exp Mol Med; 2019 Jun; 51(6):1-12. PubMed ID: 31160603
[TBL] [Abstract][Full Text] [Related]
24. A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
Fox BP; Kandpal RP
Cancer Genomics Proteomics; 2011; 8(4):185-93. PubMed ID: 21737611
[TBL] [Abstract][Full Text] [Related]
25. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel reversed trastuzumab resistance via regulating JUN in human gastric cancer cells identified by FAN analysis.
Wang Z; Zou F; Tian Y; Xiang B; Qin B; Liu Y
Future Oncol; 2018 Nov; 14(26):2701-2712. PubMed ID: 30265158
[TBL] [Abstract][Full Text] [Related]
27. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
[TBL] [Abstract][Full Text] [Related]
28. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
29. Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.
Yoon S; Lee EJ; Choi JH; Chung T; Kim DY; Im JY; Bae MH; Kwon JH; Kim HH; Kim HC; Park YN; Wang HJ; Woo HG
Oncogene; 2018 Aug; 37(32):4443-4454. PubMed ID: 29720727
[TBL] [Abstract][Full Text] [Related]
30. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Toosi BM; El Zawily A; Truitt L; Shannon M; Allonby O; Babu M; DeCoteau J; Mousseau D; Ali M; Freywald T; Gall A; Vizeacoumar FS; Kirzinger MW; Geyer CR; Anderson DH; Kim T; Welm AL; Siegel P; Vizeacoumar FJ; Kusalik A; Freywald A
Oncogene; 2018 Jul; 37(30):4073-4093. PubMed ID: 29700392
[TBL] [Abstract][Full Text] [Related]
31. The role of cadherin-11 in microcystin-LR-induced migration and invasion in colorectal carcinoma cells.
Zhu Q; Wang Z; Zhou L; Ren Y; Gong Y; Qin W; Bai L; Hu J; Wang T
Oncol Lett; 2018 Feb; 15(2):1417-1422. PubMed ID: 29399188
[TBL] [Abstract][Full Text] [Related]
32. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
Shen Q; Eun JW; Lee K; Kim HS; Yang HD; Kim SY; Lee EK; Kim T; Kang K; Kim S; Min DH; Oh SN; Lee YJ; Moon H; Ro SW; Park WS; Lee JY; Nam SW
Hepatology; 2018 Apr; 67(4):1360-1377. PubMed ID: 29059470
[TBL] [Abstract][Full Text] [Related]
33. Vinculin in cell-cell and cell-matrix adhesions.
Bays JL; DeMali KA
Cell Mol Life Sci; 2017 Aug; 74(16):2999-3009. PubMed ID: 28401269
[TBL] [Abstract][Full Text] [Related]
34. The cancer cell adhesion resistome: mechanisms, targeting and translational approaches.
Dickreuter E; Cordes N
Biol Chem; 2017 Jun; 398(7):721-735. PubMed ID: 28002024
[TBL] [Abstract][Full Text] [Related]
35.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
36. Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration.
Birtolo C; Pham H; Morvaridi S; Chheda C; Go VL; Ptasznik A; Edderkaoui M; Weisman MH; Noss E; Brenner MB; Larson B; Guindi M; Wang Q; Pandol SJ
Am J Pathol; 2017 Jan; 187(1):146-155. PubMed ID: 27855278
[TBL] [Abstract][Full Text] [Related]
37. Cadherin-11 is a novel regulator of extracellular matrix synthesis and tissue mechanics.
Row S; Liu Y; Alimperti S; Agarwal SK; Andreadis ST
J Cell Sci; 2016 Aug; 129(15):2950-61. PubMed ID: 27311482
[TBL] [Abstract][Full Text] [Related]
38. Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.
Yuan H; Sun B; Gao F; Lan M
Pharm Biol; 2016 Nov; 54(11):2629-2635. PubMed ID: 27159496
[TBL] [Abstract][Full Text] [Related]
39. Cadherin-11 localizes to focal adhesions and promotes cell-substrate adhesion.
Langhe RP; Gudzenko T; Bachmann M; Becker SF; Gonnermann C; Winter C; Abbruzzese G; Alfandari D; Kratzer MC; Franz CM; Kashef J
Nat Commun; 2016 Mar; 7():10909. PubMed ID: 26952325
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
